(0.19%) 5 532.25 points
(0.14%) 39 524 points
(0.18%) 19 964 points
(0.75%) $82.15
(-0.92%) $2.58
(-0.19%) $2 335.10
(-0.45%) $29.11
(-0.58%) $1 008.20
(-0.34%) $0.930
(-0.47%) $10.63
(-0.13%) $0.790
(1.51%) $87.02
Live Chart Being Loaded With Signals
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage...
Stats | |
---|---|
本日の出来高 | 666 437 |
平均出来高 | 1.38M |
時価総額 | 416.10M |
EPS | $-0.250 ( Q2 | 2023-12-31 ) |
次の収益日 | ( $0 ) 2024-08-28 |
Last Dividend | $0.111 ( 2004-10-11 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.820 (Sector) 0 (Industry) 0 |
ATR14 | $0.00300 (0.86%) |
ボリューム 相関
Opthea Ltd 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Opthea Ltd 相関 - 通貨/商品
Opthea Ltd 財務諸表
Annual | 2023 |
収益: | $161 163 |
総利益: | $-89 309.00 (-55.42 %) |
EPS: | $-0.450 |
FY | 2023 |
収益: | $161 163 |
総利益: | $-89 309.00 (-55.42 %) |
EPS: | $-0.450 |
FY | 2022 |
収益: | $125 047 |
総利益: | $-107 422 (-85.91 %) |
EPS: | $-0.340 |
FY | 2021 |
収益: | $68 613.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.195 |
Financial Reports:
No articles found.
Opthea Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.111 | 2004-10-11 |
Last Dividend | $0.111 | 2004-10-11 |
Next Dividend | $0 | N/A |
Payout Date | 2004-11-01 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.111 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2004 | $0.111 | 5.43% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
11 Oct 2004 | $0.111 | 25 Aug 2004 | 15 Oct 2004 | 01 Nov 2004 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
EZL.AX | Dividend Royal | 2024-02-02 | Semi-Annually | 24 | 11.64% | 8.24 |
GRR.AX | Dividend Royal | 2024-03-12 | Semi-Annually | 14 | 11.88% | 7.99 |
RKN.AX | Dividend Royal | 2023-08-31 | Annually | 22 | 15.73% | 7.24 |
TWR.AX | Dividend King | 2024-06-12 | Annually | 25 | 5.98% | 7.21 |
YAL.AX | Dividend Royal | 2024-03-12 | Annually | 7 | 12.76% | 7.18 |
SHM.AX | Dividend Royal | 2024-03-14 | Semi-Annually | 9 | 14.97% | 7.14 |
HZN.AX | Dividend Royal | 2024-04-18 | Semi-Annually | 4 | 18.99% | 7.06 |
BHP.AX | Dividend Royal | 2024-03-07 | Semi-Annually | 37 | 6.46% | 6.97 |
CDD.AX | Ex Dividend King | 2024-05-24 | Annually | 21 | 91.43% | 6.79 |
KSL.AX | Dividend Royal | 2024-03-05 | Semi-Annually | 9 | 9.58% | 6.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1 383.77 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.467 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 8.77 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.10 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.00 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.82 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.000780 | -1.500 | 9.99 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -8.08 | 1.000 | -4.10 | -4.10 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.204 | [0 - 30] |
freeCashFlowPerShareTTM | -0.306 | 2.00 | -0.153 | -0.306 | [0 - 20] |
debtEquityRatioTTM | -0.00277 | -1.500 | -0.0111 | 0.0166 | [0 - 2.5] |
grossProfitMarginTTM | -0.169 | 1.000 | -6.15 | -6.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1 413.43 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1 397.12 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00106 | 0.800 | -3.33 | -2.66 | [0.5 - 2] |
Total Score | -0.994 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.561 | 1.000 | -0.158 | 0 | [1 - 100] |
returnOnEquityTTM | 8.77 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.306 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.204 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0585 | 1.500 | -3.72 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1 027.63 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.615 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Opthea Ltd
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。